Advertisement

Botulinum Neurotoxin: Basic Facts, Physiology and Pharmacology

  • M. G. BerryEmail author
Chapter

Abstract

Globally recognised botulinum neurotoxin is known primarily for its aesthetic effects. It seems to attract a negative media slant disproportionate to its wealth of clinically documented attributes in fields as disparate as paediatrics, urology, ophthalmology and, most recently, neurology for its treatment of migraine. This chapter introduces some of its important facts, fundaments of physiology and basic pharmacology.

Keywords

Botulinum Neurotoxin Botox® Botulism Evidence-based Neuromuscular blockade Safety Complications 

Notes

Acknowledgement

Conflict of Interest: The author has no conflict of interest to declare.

References

  1. 1.
    Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285:1059–70.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    van Ermengen EP. Über einen neuen anaëroben Bacillus and seine Beziehungen zum Botulismus. Z Hyg Infektionskrankh. 1897;26:1–56.Google Scholar
  3. 3.
    Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044–9.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Scott AB, Kennedy RA, Stubbs HA. Botulinum toxin A injection as a treatment for blepharospasm. Arch Opththalmol. 1985;103:347–50.CrossRefGoogle Scholar
  5. 5.
    Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18:17–21.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
  7. 7.
    Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;56:80–99.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Sugiyama H. Clostridium botulinum neurotoxin. Microbiol Rev. 1980;44:419–48.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Smith TJ, Hill KK, Raphael BH. Historical and current perspectives on Clostridium botulinum diversity. Res Microbiol. 2015;166:290–302.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998;5:898–902.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Rawlings ND, Barrett AJ. Homologues of insulinase, a new superfamily of metalloendopeptidases. Biochem J. 1991;275:389–91.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Miyata K, Yoneyama T, Suzuki T, et al. Expression and stability of the nontoxic component of the botulinum toxin complex. Biochem Biophys Res Commun. 2009;384:126–30.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Swaminathan S, Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol. 2000;7:693–9.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Setlow P. I will survive: DNA protection in bacterial spores. Trends Microbiol. 2007;15:172–80.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Pickett J, Berg B, Chaplin E, Brunstetter-Shafer MA. Syndrome of botulism in infancy: clinical and electrophysiological study. N Engl J Med. 1976;295:770–2.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Cartee TV, Monheit GD. An overview of botulinum toxins: past, present, and future. Clin Plast Surg. 2011;38:409–26.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949;109:10–24.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Dolly JO, Black J, Williams RS, Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature. 1984;307:457–60.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Koriazova LK, Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol. 2003;10:13–8.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000;80:717–66.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Lagow RD, Bao H, Cohen EN, et al. Modification of a hydrophobic layer by a point mutation in syntaxin 1A regulates the rate of synaptic vesicle fusion. PLoS Biol. 2007;5:e72.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Barr JR, Moura H, Boyer AE, et al. Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg Infect Dis. 2005;11:1578–83.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Montecucco C, Schiavo G, Pantano S. SNARE complexes and neuroexocytosis: how many, how close? Trends Biochem Sci. 2005;30:367–72.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve. 2009;40:374–80.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett. 1997;224:91–4.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Johnson EA, Montecucco C. Botulism. Handb Clin Neurol. 2008;91:333–68.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20:981–90.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Allergan, Inc. Irvine, CA, USA Botox® Cosmetic; package insert.Google Scholar
  29. 29.
    Ipsen Biopharm Ltd., Wrexham, UK; package insert.Google Scholar
  30. 30.
    Merz Pharmaceuticals GmbH, Frankfurt, Germany; package insert.Google Scholar
  31. 31.
    Lowe NJ. Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives. Dermatol Surg. 1998;24:1216–8.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Klein AW, Carruthers A, Fagien S, Lowe NJ. Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg. 2008;121:413e–22e.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Sanders DB, Massey EW, Buckley EG. Botulinum toxin for blepharospasm: single-fibre EMG studies. Neurology. 1986;36:545–7.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Osako M, Keltner JL. Botulinum A toxin (Oculinum) in ophthalmology. Surv Ophthalmol. 1991;36:28–46.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96:3200–5.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Angaut-Petit D, Molgó J, Comella JX, Faille L, Tabti N. Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience. 1990;37:799–808.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Guyuron B, Tucker T, Kriegler J. Botulinum toxin A and migraine surgery. Plast Reconstr Surg. 2003;112:171S–3S.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Burstein R, Zhang X, Levy D, Aoki K, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia. 2014;34:853–69.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord. 1988;3:333–5.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Scott AB, Magoon EH, McNeer KW, Stager DR. Botulinum treatment of strabismus in children. Trans Am Ophthalmol Soc. 1989;87:174–80.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Carruthers A. Problems with toxins. Body Lang. 2010;35:43–4.Google Scholar
  42. 42.
    Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53:407–15.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Li M, Goldberger BA, Hopkins C. Fatal case of BOTOX-related anaphylaxis. J Forensic Sci. 2005;50:169–72.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Bai L, Peng X, Liu Y, et al. Clinical analysis of 86 botulism cases caused by cosmetic injection of botulinum toxin (BoNT). Medicine (Baltimore). 2018;97:e10659.CrossRefGoogle Scholar
  45. 45.
    Claus D, Druschky A, Erbguth F. Botulinum toxin: influence on respiratory heart rate variation. Mov Disord. 1995;10:574–9.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Tyler HR. Botulinus toxin: effect on the central nervous system of man. Science. 1963;139:847–8.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Marinelli S, Vacca V, Ricordy R, et al. The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS One. 2012;7:e47977.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Matak I, Lacković Z. Botulinum toxin A, brain and pain. Prog Neurobiol. 2014;119–120:39–59.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Söylev MF, Koçak N, Kuvaki B, Ozkan SB, Kir E. Anaesthesia with EMLA cream for botulinum A toxin injection into eyelids. Ophthalmologica. 2002;216:355–8.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Eppley BL. Easing Botox administration with EMLA cream. Aesthet Surg J. 2004;24:79–81.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Sami MS, Soparka CNS, Patrinely JR, Hollier LM, Hollier LH. Efficacy of Botulinum toxin type A after topical anaesthesia. Ophthal Plast Reconstr Surg. 2006;22:448–5.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Brin MF, Boodhoo T, Pogoda JM, et al. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol. 2009;61:961–70.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69:200–35.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety and antibody frequency. J Neurol. 1999;246:265–74.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord. 2010;25:2211–8.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol. 2009;32:213–8.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Lee SK. Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. Dermatol Surg. 2007;33:S105–10.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Flynn TC, Clark RE 2nd. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg. 2003;29:519–22.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Dressler D, Rothwell JC. Electromyographic quantification of the paralyzing effect of botulinum toxin in the sternocleidomastoid muscle. Eur Neurol. 2000;43:13–6.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.London Welbeck HospitalLondonUK

Personalised recommendations